MedPath

Cabazitaxel

Generic Name
Cabazitaxel
Brand Names
Jevtana, Cabazitaxel Accord
Drug Type
Small Molecule
Chemical Formula
C45H57NO14
CAS Number
183133-96-2
Unique Ingredient Identifier
51F690397J
Background

Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.

Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.

Indication

用于治疗转移性去势抵抗性前列腺癌患者。

Associated Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical Trials
Related News

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Phase 2
Recruiting
Conditions
Metastatic Prostate Cancer
Metastatic Prostate Neuroendocrine Carcinoma
Interventions
First Posted Date
2021-01-14
Last Posted Date
2025-02-14
Lead Sponsor
Andrew J. Armstrong, MD
Target Recruit Count
43
Registration Number
NCT04709276
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

Phase 2
Not yet recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2020-11-10
Last Posted Date
2021-01-05
Lead Sponsor
The Clatterbridge Cancer Centre NHS Foundation Trust
Target Recruit Count
120
Registration Number
NCT04622761

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Metastatic Prostate Neuroendocrine Carcinoma
Aggressive Variant Prostate Carcinoma
Metastatic Prostate Small Cell Carcinoma
Interventions
First Posted Date
2020-10-19
Last Posted Date
2025-01-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
120
Registration Number
NCT04592237
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Phase 2
Completed
Conditions
Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions
First Posted Date
2020-07-31
Last Posted Date
2023-08-09
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT04495179
Locations
🇪🇸

Research Site, Madrid, Spain

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase 2
Active, not recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2019-05-02
Last Posted Date
2024-02-28
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
22
Registration Number
NCT03934840
Locations
🇺🇸

Thomas Jeferson University, Philadelphia, Pennsylvania, United States

🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 5 locations

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

First Posted Date
2019-04-04
Last Posted Date
2025-04-09
Lead Sponsor
Karolinska Institutet
Target Recruit Count
750
Registration Number
NCT03903835
Locations
🇳🇴

Akershus Universitetssykehus, Lørenskog, Norway

🇧🇪

OLV Ziekenhuis Aalst, Aalst, Belgium

🇧🇪

Ziekenhuis Oost-Limburg, Genk, Belgium

and more 29 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Biological: Bevacizumab
Procedure: Biospecimen Collection
Biological: Durvalumab
Biological: Ipilimumab
Biological: Nivolumab
Biological: Pembrolizumab
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab Emtansine
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

Phase 2
Terminated
Conditions
Metastatic Prostate Cancer
Interventions
First Posted Date
2018-12-05
Last Posted Date
2025-04-13
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Target Recruit Count
57
Registration Number
NCT03764540
Locations
🇨🇦

Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada

Multi-academic Center Study of Xofigo Patients

Completed
Conditions
Prostate Cancer, Castration Resistant
Interventions
First Posted Date
2018-02-05
Last Posted Date
2020-10-22
Lead Sponsor
Bayer
Target Recruit Count
150
Registration Number
NCT03419442
Locations
🇺🇸

Bayer US, Whippany, New Jersey, United States

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Phase 2
Active, not recruiting
Conditions
Stage IV Prostate Adenocarcinoma AJCC v7
Prostate Carcinoma Metastatic in the Bone
Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma in the Soft Tissue
Interventions
Drug: Antiandrogen Therapy
Other: Laboratory Biomarker Analysis
Procedure: Orchiectomy
Other: Pharmacological Study
First Posted Date
2018-02-01
Last Posted Date
2025-01-29
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
223
Registration Number
NCT03419234
Locations
🇺🇸

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

🇺🇸

Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States

🇺🇸

Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States

and more 668 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy